NCT02514239 Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients Status COMPLETED Phase PHASE1
NCT02514174 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Status COMPLETED Phase PHASE4
NCT02513459 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease Status COMPLETED Phase PHASE2
NCT02513446 Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects Status COMPLETED Phase PHASE1
NCT02506517 A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene Status COMPLETED Phase PHASE2
NCT02496585 Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis Status COMPLETED Phase PHASE2
NCT02491099 A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Status RECRUITING Phase PHASE2
NCT02489981 Specific Use-result Surveillance of Spiriva Respimat in Asthmatics Status COMPLETED Phase N/A
NCT02489968 Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE3
NCT02489942 Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus Status COMPLETED Phase N/A
NCT02483416 Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance Status TERMINATED Phase N/A
NCT02453555 Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE3
NCT02450656 Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer Status UNKNOWN Phase PHASE1/PHASE2
NCT02443298 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma Status COMPLETED Phase PHASE2